JP2024531437A5 - - Google Patents

Info

Publication number
JP2024531437A5
JP2024531437A5 JP2024510674A JP2024510674A JP2024531437A5 JP 2024531437 A5 JP2024531437 A5 JP 2024531437A5 JP 2024510674 A JP2024510674 A JP 2024510674A JP 2024510674 A JP2024510674 A JP 2024510674A JP 2024531437 A5 JP2024531437 A5 JP 2024531437A5
Authority
JP
Japan
Prior art keywords
solvate
formula
salt
disorder
mdma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024510674A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024531437A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2022/051269 external-priority patent/WO2023019369A1/en
Publication of JP2024531437A publication Critical patent/JP2024531437A/ja
Publication of JP2024531437A5 publication Critical patent/JP2024531437A5/ja
Pending legal-status Critical Current

Links

JP2024510674A 2021-08-20 2022-08-22 (r)-3,4-メチレンジオキシメタンフェタミン及び(s)-3,4-メチレンジオキシメタンフェタミン又は(r)n-メチル-1,3-ベンゾジオキソリルブタンアミン及び(s)n-メチル-1,3-ベンゾジオキソリルブタンアミンの非ラセミ混合物を含む組成物、並びにその使用 Pending JP2024531437A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163235460P 2021-08-20 2021-08-20
US63/235,460 2021-08-20
US202263298820P 2022-01-12 2022-01-12
US63/298,820 2022-01-12
PCT/CA2022/051269 WO2023019369A1 (en) 2021-08-20 2022-08-22 Compositions comprising non-racemic mixtures of (r)- and (s)-3,4-methylenedioxymethamphetamine or (r) and (s) n-methyl-1,3-benzodioxolylbutanamine and uses thereof

Publications (2)

Publication Number Publication Date
JP2024531437A JP2024531437A (ja) 2024-08-29
JP2024531437A5 true JP2024531437A5 (cg-RX-API-DMAC10.html) 2025-09-01

Family

ID=85239329

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024510674A Pending JP2024531437A (ja) 2021-08-20 2022-08-22 (r)-3,4-メチレンジオキシメタンフェタミン及び(s)-3,4-メチレンジオキシメタンフェタミン又は(r)n-メチル-1,3-ベンゾジオキソリルブタンアミン及び(s)n-メチル-1,3-ベンゾジオキソリルブタンアミンの非ラセミ混合物を含む組成物、並びにその使用

Country Status (8)

Country Link
US (3) US12053452B2 (cg-RX-API-DMAC10.html)
EP (1) EP4387612A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024531437A (cg-RX-API-DMAC10.html)
KR (1) KR20240061644A (cg-RX-API-DMAC10.html)
AU (2) AU2022330718B2 (cg-RX-API-DMAC10.html)
CA (1) CA3229363A1 (cg-RX-API-DMAC10.html)
IL (1) IL310937A (cg-RX-API-DMAC10.html)
WO (1) WO2023019369A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3221280A1 (en) 2021-06-03 2022-12-08 Arcadia Medicine, Inc. Enantiomeric entactogen compositions and methods of their use
WO2023283386A2 (en) * 2021-07-07 2023-01-12 Arcadia Medicine, Inc. Safer psychoactive compositions
US12492178B2 (en) 2021-09-01 2025-12-09 Empathbio, Inc. Stable polymorph of R-MDMA HCl
US11912680B2 (en) 2021-12-28 2024-02-27 Empathbio, Inc. Nitric oxide releasing prodrugs of MDA and MDMA
CA3254727A1 (en) * 2022-03-31 2023-10-05 Transcend Therapeutics, Inc. PSYCHOACTIVE MEDICINES AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC AND NEUROLOGICAL DISORDERS AND DISORDERS
US20240217944A1 (en) * 2022-12-31 2024-07-04 ATAI Therapeutics AG Salt forms of r-mdma and methods using the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3204457A1 (en) * 2021-01-06 2022-07-14 Ben SESSA Mdma in the treatment of alcohol use disorder
US20220347195A1 (en) 2021-05-03 2022-11-03 Mind Medicine, Inc. Psychedelics for treatment of pain
EP4333979A4 (en) 2021-05-03 2025-01-15 Mind Medicine, Inc. Method of titrating dose of psychedelics
WO2022235514A1 (en) 2021-05-04 2022-11-10 Mind Medicine, Inc. Liposome delivery of psychedelics
US12611399B2 (en) 2021-05-04 2026-04-28 Definium Therapeutics US, Inc. Movement disorders
JP2024516421A (ja) * 2021-05-05 2024-04-15 マインド メディシン, インコーポレイテッド Mdma鏡像異性体
WO2022232949A1 (en) * 2021-05-06 2022-11-10 Pharmala Biotech Inc. Processes for the preparation of the enantiomers of 3,4-methylenedioxymethamphetamine (mdma) and n-methyl-1,3-benzodioxolylbutanamine (mbdb)
WO2022232948A1 (en) * 2021-05-06 2022-11-10 Pharmala Biotech Inc. Processes for the preparation of the enantiomers of 3,4-methylenedioxymethamphetamine (mdma) and n-methyl-1,3-benzodioxolylbutanamine (mbdb)
CA3221280A1 (en) * 2021-06-03 2022-12-08 Arcadia Medicine, Inc. Enantiomeric entactogen compositions and methods of their use
EP4408407A4 (en) 2021-09-30 2025-08-13 ATAI Life Sciences AG ENANTIOMER RATIOS OF 3,4-METHYLENEDIOXYMETHAMPHETAMINE AND RELATED METABOLITES AND RELATED USES
CA3242786A1 (en) 2022-01-07 2023-07-13 Universitatsspital Basel R-MDMA AND S-MDMA TO AID PSYCHOTHERAPY

Similar Documents

Publication Publication Date Title
EP3043785B1 (en) Application of r-ketamine and salt thereof as pharmaceuticals
JP2023530092A5 (cg-RX-API-DMAC10.html)
JP4634008B2 (ja) 2h−ベンズイミダゾール−2−オン、1,3−ジヒドロ−1−(2−{4−[3−(トリフルオロメチル)フェニル]−1−ピペラジニル}エチル)−及びその生理学的に許容される酸付加塩の新規使用
JP2021519267A5 (cg-RX-API-DMAC10.html)
JP2024516421A (ja) Mdma鏡像異性体
JP7781768B2 (ja) 神経学的および精神障害の治療方法
CZ302842B6 (cs) Farmaceutický prostredek
CN118576586A (zh) 治疗神经和精神疾病的方法
JP2023508469A5 (cg-RX-API-DMAC10.html)
JP2009526821A (ja) 注意欠陥多動性障害治療用の新規な医薬組成物
JP2011510014A5 (cg-RX-API-DMAC10.html)
JP2005539068A5 (cg-RX-API-DMAC10.html)
JP2012144545A (ja) アルファ−2−デルタリガンドとセロトニン/ノルアドレナリン再取込み阻害薬を含む組合せ
JP2007505095A (ja) うつ病及び不安障害の治療のためのアルファ−2−デルタリガンド及びssri及び/又はsnriを含む組み合わせ
US20240065988A1 (en) Combined use of ketamine and retigabine (ezogabine) for the treatment of psychiatric disorders
US20260000641A1 (en) Isotopically enriched analogs of 5,6-methylenedioxy-2-aminoindane (imdai)
CN113710319A (zh) 用于治疗焦虑相关病症的组合物和方法
US10647679B2 (en) N-methyl-D-aspartate receptor (NMDAR) potentiators, pharmaceutical compositions, and uses related thereto
WO2023081899A1 (en) Isotopically enriched n-methyl-1,3-benzodioxolylbutanamine (mbdb) and stereoisomers thereof
JP2023506480A (ja) アルツハイマー病の治療のための化合物
JP2022543203A5 (cg-RX-API-DMAC10.html)
JP2007527905A (ja) アルファ−2−デルタリガンドを含む組合せ
JP2025501411A5 (cg-RX-API-DMAC10.html)
CN104884060A (zh) 治疗方案
CN1407890A (zh) 牛皮癣的治疗